Skip to main content
Advertisement

Main menu

  • Home
  • Content
    • Current Issue
    • Publication Preview--Ahead of Print
    • Past Issue Archive
    • Case of the Week Archive
    • Classic Case Archive
    • Case of the Month Archive
    • COVID-19 Content and Resources
  • For Authors
  • About Us
    • About AJNR
    • Editors
    • American Society of Neuroradiology
  • Submit a Manuscript
  • Podcasts
    • Subscribe on iTunes
    • Subscribe on Stitcher
  • More
    • Subscribers
    • Permissions
    • Advertisers
    • Alerts
    • Feedback
  • Other Publications
    • ajnr

User menu

  • Subscribe
  • Alerts
  • Log in

Search

  • Advanced search
American Journal of Neuroradiology
American Journal of Neuroradiology

American Journal of Neuroradiology

  • Subscribe
  • Alerts
  • Log in

Advanced Search

  • Home
  • Content
    • Current Issue
    • Publication Preview--Ahead of Print
    • Past Issue Archive
    • Case of the Week Archive
    • Classic Case Archive
    • Case of the Month Archive
    • COVID-19 Content and Resources
  • For Authors
  • About Us
    • About AJNR
    • Editors
    • American Society of Neuroradiology
  • Submit a Manuscript
  • Podcasts
    • Subscribe on iTunes
    • Subscribe on Stitcher
  • More
    • Subscribers
    • Permissions
    • Advertisers
    • Alerts
    • Feedback
  • Follow AJNR on Twitter
  • Visit AJNR on Facebook
  • Follow AJNR on Instagram
  • Join AJNR on LinkedIn
  • RSS Feeds
LetterLetter

Persistence of Gadolinium Contrast Enhancement in CSF: A Possible Harbinger of Gadolinium Neurotoxicity?

F.K. Hui and M. Mullins
American Journal of Neuroradiology January 2009, 30 (1) e1; DOI: https://doi.org/10.3174/ajnr.A1205
F.K. Hui
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Mullins
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
Loading

Gadolinium chelates are relatively safe agents, with occasional hypersensitivity reactions and systemic toxicity with predominantly extracellular distribution and primarily glomerular clearance. Neurotoxicity has been estimated at approximately 1% on initial studies regarding the pharmacokinetics of gadolinium.1

We recently encountered a patient who, after receiving MR imaging and contrast MR angiography for a syncopal work-up, became encephalopathic. A follow-up MR imaging showed homogeneous T1 shortening and fluid-attenuated inversion recovery hyperintensity in the CSF (Fig 1). Lumbar puncture performed at that time yielded CSF that also demonstrated T1 shortening. Mass spectrometry yielded a concentration of 23,000 nmol/mL of gadolinium. The patient improved after serial hemodialysis sessions to baseline.

During interpretation of the second MR imaging, we recalled a similar report by Maramattom et al,2 who described a 57-year-old woman with end stage renal failure, who developed encephalopathy after repeated intravenous gadolinium-enhanced MR imaging. On the basis of the temporal relationship of the gadolinium chelate administration and the resolution after dialysis, they suggested a diagnosis of gadolinium-related encephalopathy.2 The authors measured CSF gadolinium levels at 28,591 ng/mL (50 nmol/mL). CSF gadolinium-related T1 shortening in the setting of renal failure was initially reported by Rai and Hogg,3 who emphasized the need for familiarity with this appearance, lest it be confused with other pathologic conditions.

In 2007, Arlt and Cepek4 described a more dramatic example of neurotoxicity in a 64-year-old woman with presumed spinal stenosis who inadvertently received 20 mL of intrathecal gadolinium dimeglumine (10 mmol), which resulted in ataxia and delirium. They measured a CSF concentration of gadolinium of 23,365 nmol/mL on day 1, which diminished to undetectable levels by day 5.

In our patient, the paramagnetic effects in the patient's CSF also likely resulted from accumulation of gadolinium chelate administered during the initial MR imaging. Ultimately, the working diagnosis of gadolinium neurotoxicity was made because no other causes for the patient's encephalopathy were discovered. Although it is known that inorganic gadolinium salts are neurotoxic, it is unclear whether the unchelated gadolinium atoms, gadolinium chelates, or the chelating agents are the culprits for neurotoxicity.

Recent reports of neurotoxicity associated with gadolinium contrast should draw renewed attention to potential, though rare, adverse affects. When diffuse T1 shortening of the CSF is encountered, we suggest that this observation should prompt inquiry as to the patient's renal status and discussion with the clinical team, who may be unaware of gadolinium-associated encephalopathy. Subclinical neurotoxicity may escape clinical attention if patients with renal failure are not specifically monitored, especially because gadolinium is efficiently removed by dialysis (95% at 3 sessions).1 We suggest that caution should be exercised when contemplating administering gadolinium chelates in this population due to diffusion of gadolinium chelates into the CSF and possible subsequent neurotoxicity.

  Fig 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig 1.

T1 precontrast MR image shows homogenous T1 shortening in the CSF.

References

  1. ↵
    Arsenault TM, King BF, Marsh JW Jr, et al. Systemic gadolinium toxicity in patients with renal insufficiency and renal failure: retrospective analysis of an initial experience. Mayo Clin Proc 1996;71:1150–54
    CrossRefPubMed
  2. ↵
    Maramattom BV, Manno EM, Wijdicks EF, et al. Gadolinium encephalopathy in a patient with renal failure. Neurology 2005;64:1276–78
    Abstract/FREE Full Text
  3. ↵
    Rai AT, Hogg JP. Persistence of gadolinium in CSF: a diagnostic pitfall in patients with end-stage renal disease. AJNR Am J Neuroradiol 2001;22:1357–61
    Abstract/FREE Full Text
  4. ↵
    Arlt S, Cepek L, Rustenbeck HH, et al. Gadolinium encephalopathy due to accidental intrathecal administration of gadopentetate dimeglumine. J Neurol 2007;254:810–12. Epub 2007 Apr 2
    CrossRefPubMed
  • Copyright © American Society of Neuroradiology
PreviousNext
Back to top

In this issue

American Journal of Neuroradiology: 30 (1)
American Journal of Neuroradiology
Vol. 30, Issue 1
January 2009
  • Table of Contents
  • Index by author
Advertisement
Print
Download PDF
Email Article

Thank you for your interest in spreading the word on American Journal of Neuroradiology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Persistence of Gadolinium Contrast Enhancement in CSF: A Possible Harbinger of Gadolinium Neurotoxicity?
(Your Name) has sent you a message from American Journal of Neuroradiology
(Your Name) thought you would like to see the American Journal of Neuroradiology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Persistence of Gadolinium Contrast Enhancement in CSF: A Possible Harbinger of Gadolinium Neurotoxicity?
F.K. Hui, M. Mullins
American Journal of Neuroradiology Jan 2009, 30 (1) e1; DOI: 10.3174/ajnr.A1205

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Persistence of Gadolinium Contrast Enhancement in CSF: A Possible Harbinger of Gadolinium Neurotoxicity?
F.K. Hui, M. Mullins
American Journal of Neuroradiology Jan 2009, 30 (1) e1; DOI: 10.3174/ajnr.A1205
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Purchase

Jump to section

  • Article
    • References
  • Figures & Data
  • Info & Metrics
  • References
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Crossref
  • Google Scholar

This article has not yet been cited by articles in journals that are participating in Crossref Cited-by Linking.

More in this TOC Section

  • Regarding “Rates of Epidural Blood Patch following Lumbar Puncture Comparing Atraumatic versus Bevel-Tip Needles Stratified for Body Mass Index”
  • CAA-ri and ARIA: Two Faces of the Same Coin?
  • Fair Performance of CT in Diagnosing Unilateral Vocal Fold Paralysis
Show more Letters

Similar Articles

Advertisement

News and Updates

  • Lucien Levy Best Research Article Award
  • Thanks to our 2022 Distinguished Reviewers
  • Press Releases

Resources

  • Evidence-Based Medicine Level Guide
  • How to Participate in a Tweet Chat
  • AJNR Podcast Archive
  • Ideas for Publicizing Your Research
  • Librarian Resources
  • Terms and Conditions

Opportunities

  • Share Your Art in Perspectives
  • Get Peer Review Credit from Publons
  • Moderate a Tweet Chat

American Society of Neuroradiology

  • Neurographics
  • ASNR Annual Meeting
  • Fellowship Portal
  • Position Statements

© 2023 by the American Society of Neuroradiology | Print ISSN: 0195-6108 Online ISSN: 1936-959X

Powered by HighWire